Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
NCT04095143 · View on ClinicalTrials.gov ↗
Study Summary
Fluid overload is associated with adverse outcomes in patients with severe acute kidney injury. It remains unclear if fluid overload is merely a marker of disease severity or if organ congestion is a mediator of complications. Point-of-care ultrasound could be a modality used to assess organ congestion and its clinical implications. The objective of this study is to determine whether ultrasound markers of organ congestion are associated with major adverse kidney events in critically ill patients with severe acute kidney injury.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Portal vein flow
- DIAGNOSTIC_TEST Intra-renal flow
- DIAGNOSTIC_TEST Hepatic vein flow
- DIAGNOSTIC_TEST Pulmonary B-lines
- DIAGNOSTIC_TEST Dimensions of the inferior vena cava
Study Locations (6)
Ontario
- Sunnybrook Health Science Centre — Toronto
- St. Michael's hospital — Toronto
Quebec
- Centre Hospitalier de l'Université de Montréal — Montreal
- Montreal Heart Institute — Montreal
Kentucky
- University of Kentucky — Lexington
Alberta
- University of Alberta — Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2022-09-01 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04095143
The ClinicalTrials.gov registry entry for NCT04095143 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centre hospitalier de l'Université de Montréal (CHUM), which has 7 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Acute Kidney Injury appearing as the primary indexed condition, and to 5 interventions — of which Portal vein flow is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04095143 reports 6 study locations spanning 4 distinct geographic areas — top geographies include Ontario, Quebec, Kentucky. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04095143 about?
NCT04095143 is a clinical study titled "Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury". Fluid overload is associated with adverse outcomes in patients with severe acute kidney injury. It remains unclear if fluid overload is merely a marker of disease severity or if organ congestion is a mediator of complications. Point-of-care ultrasound could be a modality used to assess organ congest...
What is the current status of trial NCT04095143?
This trial is currently completed. The enrollment target is 125 participants. The study started on 2018-09-04. Estimated completion is 2022-09-01.
What conditions does trial NCT04095143 study?
This clinical trial studies the following conditions: Acute Kidney Injury, Fluid Overload, Ultrasonography. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04095143?
The interventions under investigation include: Portal vein flow (DIAGNOSTIC_TEST), Intra-renal flow (DIAGNOSTIC_TEST), Hepatic vein flow (DIAGNOSTIC_TEST), Pulmonary B-lines (DIAGNOSTIC_TEST), Dimensions of the inferior vena cava (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04095143?
This trial is sponsored by Centre hospitalier de l'Université de Montréal (CHUM), which has 7 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04095143 being conducted?
This trial has 6 study locations across Kentucky, Alberta, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.